NeoGenomics, Inc. (NEO) vs ARS Pharmaceuticals, Inc. (SPRY)
A side-by-side comparison of NeoGenomics, Inc. and ARS Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NEO
NeoGenomics, Inc.
$16.73HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
SPRY
ARS Pharmaceuticals, Inc.
$4.28HealthcareDelayed quote: Oct 6, 2026, 2:25 PM EDT
Total return — NEO vs SPRY
growth of $100 · dividends reinvested · last 6yNEO -59.3% (-13.9%/yr)SPRY -82.8% (-25.5%/yr)NEO compounded faster over this window
NEO SPRY
NEO vs SPRY: by the numbers
- •NEO is the larger company ($430M vs $425M market cap).
- •Both run net losses; NEO's is the smaller (-6.77% vs -184.24% net margin).
- •SPRY grew revenue faster over the past five years (36.43% vs 9.41% CAGR).
Metrics side by side
Valuation
| Metric | NEO | SPRY |
|---|---|---|
| Forward P/E | 91.56 | N/A |
| P/S ratio | 0.56 | 3.64 |
| P/B ratio | 0.55 | 33.98 |
Profitability
| Metric | NEO | SPRY |
|---|---|---|
| Gross margin | 42.92% | 73.89% |
| Operating margin | -8.63% | -212.92% |
| Net margin | -6.77% | -184.24% |
| ROE | -6.60% | -1721.80% |
| ROIC | -5.29% | -114.65% |
Growth (annualized)
| Metric | NEO | SPRY |
|---|---|---|
| Revenue CAGR (5Y) | 9.41% | 36.43% |
| Total return CAGR (5Y) | -15.14% | -16.35% |
Frequently asked
- Which has grown faster, NEO or SPRY?
- Over the past five years, SPRY grew revenue faster — NEO at a 9.41% CAGR versus SPRY at 36.43%.
- How have NEO and SPRY total returns compared?
- Over the past 5 years, NEO delivered -15.14% and SPRY delivered -16.35% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
NeoGenomics ROEARS Pharmaceuticals ROENeoGenomics operating marginARS Pharmaceuticals operating marginNeoGenomics revenue growthARS Pharmaceuticals revenue growthNeoGenomics free cash flowARS Pharmaceuticals free cash flow
NeoGenomics & ARS Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.